首页> 美国卫生研究院文献>World Journal of Gastrointestinal Oncology >Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas
【2h】

Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas

机译:胰腺导管内乳头状黏液性肿瘤的病理特征及诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a noninvasive epithelial neoplasm of mucin-producing cells arising in the main duct (MD) and/or branch ducts (BD) of the pancreas. Involved ducts are dilated and filled with neoplastic papillae and mucus in variable intensity. IPMN lacks ovarian-type stroma, unlike mucinous cystic neoplasm, and is defined as a grossly visible entity (≥ 5 mm), unlike pancreatic intraepithelial neoplasm. With the use of high-resolution imaging techniques, very small IPMNs are increasingly being identified. Most IPMNs are solitary and located in the pancreatic head, although 20%-40% are multifocal. Macroscopic classification in MD type, BD type and mixed or combined type reflects biological differences with important prognostic and preoperative clinical management implications. Based on cytoarchitectural atypia, IPMN is classified into low-grade, intermediate-grade and high-grade dysplasia. Based on histological features and mucin (MUC) immunophenotype, IPMNs are classified into gastric, intestinal, pancreatobiliary and oncocytic types. These different phenotypes can be observed together, with the IPMN classified according to the predominant type. Two pathways have been suggested: gastric phenotype corresponds to less aggressive uncommitted cells (MUC1 -, MUC2 -, MUC5AC +, MUC6 +) with the capacity to evolve to intestinal phenotype (intestinal pathway) (MUC1 -, MUC2 +, MUC5AC +, MUC6 - or weak +) or pancreatobiliary /oncocytic phenotypes (pyloropancreatic pathway) (MUC1 +, MUC 2-, MUC5AC +, MUC 6 +) becoming more aggressive. Prognosis of IPMN is excellent but critically worsens when invasive carcinoma arises (about 40% of IPMNs), except in some cases of minimal invasion. The clinical challenge is to establish which IPMNs should be removed because of their higher risk of developing invasive cancer. Once resected, they must be extensively sampled or, much better, submitted in its entirety for microscopic study to completely rule out associated invasive carcinoma.
机译:胰腺的导管内乳头状粘液性肿瘤(IPMN)是在胰腺的主导管(MD)和/或分支导管(BD)中产生的产生粘蛋白的细胞的非侵入性上皮肿瘤。累及的导管被扩张,并充满不同强度的赘生性乳头和粘液。与粘液性囊性肿瘤不同,IPMN缺乏卵巢型基质,与胰腺上皮内肿瘤不同,IPMN被定义为肉眼可见的实体(≥5 mm)。随着高分辨率成像技术的使用,越来越多的小型IPMN被识别出来。尽管20%-40%是多灶性的,但大多数IPMN是单发的,位于胰头。 MD型,BD型和混合型或组合型的宏观分类反映了生物学差异,对预后和术前的临床管理具有重要意义。根据细胞结构性非典型性,IPMN分为低度,中度和高度不典型增生。根据组织学特征和粘蛋白(MUC)免疫表型,IPMNs可分为胃,肠,胰胆管和溶细胞型。可以一起观察这些不同的表型,并根据主要类型对IPMN进行分类。已经提出了两种途径:胃表型对应于侵袭性较低的未定型细胞(MUC1-,MUC2-,MUC5AC +,MUC6 +),具有进化为肠表型的能力(肠途径)(MUC1-,MUC2 +,MUC5AC +,MUC6 -或弱+)或胰胆管/吞噬细胞表型(焦胰途径)(MUC1 +,MUC 2-,MUC5AC +,MUC 6 +)变得更具攻击性。 IPMN的预后极好,但当发生浸润性癌(约占IPMN的40%)时,IPMN的预后将严重恶化,除了在某些微创情况下。临床挑战是​​确定哪些IPMN因其发展为浸润性癌症的风险较高而应予以清除。切除后,必须对其进行大量采样,或者更好地将其完整提交显微镜研究,以完全排除相关的浸润性癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号